Healthcare Private Placement and M&A Transactions Review Week Ending November 24, 2024

Enveda Biosciences: The company is reportedly seeking $130 million of Series C venture funding in a deal led by FPV Ventures and Kinnevik as of June 14, 2024. Premji Invest, Baillie Gifford, Cresset Partners, True Ventures, Lux Capital, Henry Kravis, The Nature Conservancy, Dimension Capital Management and Lingotto also participated in the round. The company is a developer of a drug analysis platform focused on the discovery of new drugs from medicinal plants within the pharmaceutical industry.

Quanta Dialysis Technologies: The company raised an estimated $60 million of Series E venture funding in a deal led by Novo Holdings, b2venture and Glenview Capital Management on November 18, 2024. The company is a manufacturer of a medical device intended to improve dialysis experiences and kidney care.

Genedit: The company raised $35 million of Series B venture funding in a deal led by DSC Investment on November 20, 2024. Sequoia Capital, Korea Investment Partners, DAYLI Partners, Loftyrock Investment, ACVC Partners, Pathway Partners (Korea), Woori Venture Partners, K2 Investment Partners, KAIC TO Ventures, Kiwoom Investment, SV Investment, Yuanta Investment, IMM INvestment Group Japan, Korea Investment & Securities, Hockey Stick Investments and Korea Development Bank also participated in the round. The company is a developer of curative therapies designed to solve gene therapy delivery challenges by systematically screening its proprietary nanoparticle library.

New Lantern: The company raised $19 million of Series A venture funding in a deal led by Benchmark Capital Holdings on November 20, 2024. Menlo Ventures, SV Angel, Afore Capital, Neo, Guillermo Rauch, Amjad Masad, Saji Wickramasekara, Jay Kreps, Position Ventures, Gokul Rajaram and other undisclosed investors also participated in the round. The company is a developer of a medical imaging platform designed to accelerate radiology with cloud and AI-powered medical image analysis.

ReCode Therapeutics: The company raised $15 million of venture funding from Cystic Fibrosis Foundation on November 18, 2024. The company is a developer of targeted delivery technology designed for patients with rare diseases.

Citizen Health: The company raised $14.5 million of venture funding in a deal led by Transformation Capital on November 19, 2024. The company is a developer of an online healthcare data platform designed to help patients collect, organize, and share their medical records digitally.

Aizen Therapeutics: The company raised $13 million of venture funding from Cercano Management, Madrona Venture Group and Wilson Hill Ventures on November 21, 2024. The company is an operator of a drug discovery firm intended to cross and modulate biological barriers.

Click Therapeutics: The company raised $11.3 million of venture funding from undisclosed investors on November 21, 2024. The company develops, validates, and commercializes software as a medical treatments prescription platform to deliver medical treatments for people with unmet medical needs.

Gliknik: The company raised $11.2 million of venture funding in the form of convertible debt from undisclosed investors on November 21, 2024. The company is an operator of a biopharmaceutical business intended to treat cancer and autoimmune diseases.

Ride Health: The company raised $10.8 million of venture funding from undisclosed investors on November 21, 2024. The company is a developer of a healthcare transportation management platform intended to improve access to care for patients who face transportation barriers.

Wellvana: The company raised $10 million of venture funding from undisclosed investors on November 18, 2024. The company is a developer of an integrated software platform designed to offer flexible full-risk models that incentivize quality of care.

Little Journey: The company raised GBP 6 million of Series A venture funding in a deal led by Par Equity on November 18, 2024. Octopus Ventures, Calm/Storm Ventures, Mercia Ventures, Northern Powerhouse Investment Fund and other undisclosed individual investors also participated in the round. The company is a developer of a virtual reality smartphone application designed to transform healthcare outcomes through enhanced patient engagement.

Strata Oncology: The company raised $6.2 million of venture funding in the form of convertible debt from undisclosed investors on November 22, 2024. The company is an operator of an oncology company intended to accelerate the impact of precision medicine for patients with cancer.

Panome Bio: The company raised $6 million of venture funding from undisclosed investors on November 21, 2024. The company is a developer of metabolomics technologies designed to facilitate biomarker discovery and metabolite profiling.

Modulo Bio: The company raised $5.9 million of venture funding from undisclosed investors on November 20, 2024. The company is a developer of digital biology mechanisms designed to accelerate the discovery of therapeutic targets harnessing autoimmunity.

Primaa: The company raised EUR 5 million of venture funding from Cenitz, Leia Capital and Clery on November 18, 2024. The company is a developer of a medical diagnostic software platform designed for automated and accurate histological diagnoses.

Oncobit: The company is in the process of raising $5 million of Series A venture funding as of November 19, 2024. The company is a developer of critical precision diagnostic and monitoring technology for personalized cancer care.

AxoSim: The company raised $3.7 million of venture funding from undisclosed investors on November 22, 2024. The company is a developer of a brain-on-a-chip platform designed to capture neurological processes in the brain and nervous system.

Cortechs.ai: The company raised an undisclosed amount of Series C venture funding in a deal led by VILAS Ventures on November 20, 2024. The company is a developer of brain image analysis software designed to offer better clinical insight through quantitative imaging.

i-Med Technology: The company raised an undisclosed amount of venture funding from 819 Capital Partners and Limburg Development and Investment Company on November 19, 2024. The company is a manufacturer of surgical instruments.

NanoVation Therapeutics: The company raised an undisclosed amount of venture funding in a deal led by Convergent Ventures on November 19, 2024. The company is a developer of gene therapy technology designed to treat and prevent multiple age-related diseases.

OncoVerity: The company raised an undisclosed amount of Series A venture funding in a deal led by Argenx and RefinedScience on November 21, 2024. The company is an operator of a biotechnology firm intended to develop targeted therapies for cancer.

Phagos: The company is in the process of raising venture funding as of November 18, 2024. The company is an operator of a biotechnology research platform intended to provide customizable drugs to replace antibiotics in animal farming.

Kate Therapeutics / Novartis: The company was acquired by Novartis for $1.1 billion on November 21, 2024. The company is an operator of a patient-focused biotechnology business intended to develop adeno-associated virus-based gene therapies to treat genetically defined muscle diseases.

Lamidey Noury Medical / Halma: The company was acquired by Halma for GBP 42 million on November 18, 2024. The company is a designer and manufacturer of electrosurgical instruments intended for vessel sealing and plasma saline resection.

Biocidin Botanicals / Capital Southwest Corp.: The company was acquired by CellCore Biosciences, via its financial sponsors Kainos Capital and Capital Southwest Corp., through an LBO on November 20, 2024 for an undisclosed amount. The company is an operator of a botanical supplements business providing clinically effective, evidence-based botanical products to support patients.

Founders Science Group / IEH Laboratories & Consulting Group: The company was acquired by IEH Laboratories & Consulting Group for an undisclosed amount on November 18, 2024. The company is an operator of a research organization intended to serve the pharmaceutical, cosmetic and personal care industries.

Gimli / Resilience: The company was acquired by Resilience for an undisclosed amount on November 21, 2024. The company is an operator of a medical data structuring firm intended to improve cancer research by unlocking data trapped in electronic medical records.

Odaiji / MadeForMed: The company was acquired by MadeForMed for an undisclosed amount on November 23, 2024. The company is a developer of medical practice management software intended to manage appointments, prescriptions, and patient records.

Olah / Verisma Systems: The company was acquired by Verisma Systems, via its financial sponsor Sope Creek, through an LBO on November 20, 2024 for an undisclosed amount. The company is a developer of a medical content management platform designed to secure, and preserve legacy clinical and financial data for healthcare organizations.

Omicinsight / Adelphi Ventures: The company entered into a definitive agreement to be acquired by Adelphi Ventures through an LBO on November 18, 2024 for an undisclosed amount. The company is a developer of imaging technology designed to visualize the therapeutic effects of Parkinson’s treatments.

Carebox / H.I.G. Growth Partners: The company was acquired by H.I.G. Growth Partners through an LBO on November 18, 2024 for an undisclosed amount. The company is a developer of an automated patient medical record platform designed to connect patients, families, and their physicians with treatment options only available in clinical trials.

Surgical Notes / Surgical Information Systems: The company was acquired by Surgical Information Systems, via its financial sponsor Nordic Capital, through an LBO on November 19, 2024 for an undisclosed amount. The company is a developer of a revenue cycle management system and electronic health record applications intended for the ambulatory surgery center industry.

Twiage / TigerConnect: The company, a subsidiary of Exeter Health Resources, was acquired by TigerConnect, via its financial sponsor Vista Equity Partners, through an LBO on November 20, 2024 for an undisclosed amount. The company is a developer of a cloud-based technology platform designed to enhance communication between first responders and hospitals.